Read Books Online and Download eBooks, EPub, PDF, Mobi, Kindle, Text Full Free.
Anticancer Drug Development Guide
Download Anticancer Drug Development Guide full books in PDF, epub, and Kindle. Read online Anticancer Drug Development Guide ebook anywhere anytime directly on your device. Fast Download speed and no annoying ads. We cannot guarantee that every ebooks is available!
Book Synopsis Anticancer Drug Development Guide by : Beverly A. Teicher
Download or read book Anticancer Drug Development Guide written by Beverly A. Teicher and published by Springer Science & Business Media. This book was released on 2013-11-11 with total page 315 pages. Available in PDF, EPUB and Kindle. Book excerpt: Experienced cancer researchers from pharmaceutical companies, government laboratories, and academia comprehensively review and describe the arduous process of cancer drug discovery and approval. They focus on using preclinical in vivo and in vitro methods to identify molecules of interest, detailing the targets and criteria for success in each type of testing and defining the value of the information obtained from the various tests. They also define each stage of clinical testing, explain the criteria for success, and outline the requirements for FDA approval. A companion volume by the same editor (Cancer Therapeutics: Experimental and Clinical Agents) reviews existing anticancer drugs and potential anticancer therapies. These two volumes in the Cancer Drug Discovery and Development series reveal how and why molecules become anticancer drugs and thus offer a blueprint for the present and the future of the field.
Book Synopsis Anticancer Drug Development Guide by : Beverly A. Teicher
Download or read book Anticancer Drug Development Guide written by Beverly A. Teicher and published by Springer Science & Business Media. This book was released on 2004-02-01 with total page 684 pages. Available in PDF, EPUB and Kindle. Book excerpt: This unique volume traces the critically important pathway by which a "molecule" becomes an "anticancer agent. " The recognition following World War I that the administration of toxic chemicals such as nitrogen mustards in a controlled manner could shrink malignant tumor masses for relatively substantial periods of time gave great impetus to the search for molecules that would be lethal to specific cancer cells. Weare still actively engaged in that search today. The question is how to discover these "anticancer" molecules. Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval, Second Edition describes the evolution to the present of preclinical screening methods. The National Cancer Institute's high-throughput, in vitro disease-specific screen with 60 or more human tumor cell lines is used to search for molecules with novel mechanisms of action or activity against specific phenotypes. The Human Tumor Colony-Forming Assay (HTCA) uses fresh tumor biopsies as sources of cells that more nearly resemble the human disease. There is no doubt that the greatest successes of traditional chemotherapy have been in the leukemias and lymphomas. Since the earliest widely used in vivo drug screening models were the murine L 1210 and P388 leukemias, the community came to assume that these murine tumor models were appropriate to the discovery of "antileukemia" agents, but that other tumor models would be needed to discover drugs active against solid tumors.
Book Synopsis Anticancer Drug Development Guide by : Beverly A. Teicher
Download or read book Anticancer Drug Development Guide written by Beverly A. Teicher and published by Humana. This book was released on 2004-02-01 with total page 451 pages. Available in PDF, EPUB and Kindle. Book excerpt: This unique volume traces the critically important pathway by which a "molecule" becomes an "anticancer agent. " The recognition following World War I that the administration of toxic chemicals such as nitrogen mustards in a controlled manner could shrink malignant tumor masses for relatively substantial periods of time gave great impetus to the search for molecules that would be lethal to specific cancer cells. Weare still actively engaged in that search today. The question is how to discover these "anticancer" molecules. Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval, Second Edition describes the evolution to the present of preclinical screening methods. The National Cancer Institute's high-throughput, in vitro disease-specific screen with 60 or more human tumor cell lines is used to search for molecules with novel mechanisms of action or activity against specific phenotypes. The Human Tumor Colony-Forming Assay (HTCA) uses fresh tumor biopsies as sources of cells that more nearly resemble the human disease. There is no doubt that the greatest successes of traditional chemotherapy have been in the leukemias and lymphomas. Since the earliest widely used in vivo drug screening models were the murine L 1210 and P388 leukemias, the community came to assume that these murine tumor models were appropriate to the discovery of "antileukemia" agents, but that other tumor models would be needed to discover drugs active against solid tumors.
Author :Elizabeth Garrett-Mayer Publisher :Springer Science & Business Media ISBN 13 :1441973583 Total Pages :674 pages Book Rating :4.4/5 (419 download)
Book Synopsis Principles of Anticancer Drug Development by : Elizabeth Garrett-Mayer
Download or read book Principles of Anticancer Drug Development written by Elizabeth Garrett-Mayer and published by Springer Science & Business Media. This book was released on 2010-12-29 with total page 674 pages. Available in PDF, EPUB and Kindle. Book excerpt: A practical guide to the design, conduction, analysis and reporting of clinical trials with anticancer drugs.
Book Synopsis Anticancer Drug Development Guide by : Beverly A. Teicher
Download or read book Anticancer Drug Development Guide written by Beverly A. Teicher and published by . This book was released on 2014-01-15 with total page 330 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Book Synopsis Handbook of Anticancer Drug Development by : Daniel Budman
Download or read book Handbook of Anticancer Drug Development written by Daniel Budman and published by Lippincott Raven. This book was released on 2003 with total page 502 pages. Available in PDF, EPUB and Kindle. Book excerpt: Perhaps no area of pharmacology has progressed further or faster than that of anticancer drugs. With this concise and informative resource, you'll explore the full spectrum of anticancer drug evolution -- from research and development, through clinical trials, to licensure and utilization.
Book Synopsis Handbook of Anticancer Pharmacokinetics and Pharmacodynamics by : Michelle A. Rudek
Download or read book Handbook of Anticancer Pharmacokinetics and Pharmacodynamics written by Michelle A. Rudek and published by Springer Science & Business Media. This book was released on 2014-01-10 with total page 836 pages. Available in PDF, EPUB and Kindle. Book excerpt: There are many steps on the road from discovery of an anticancer drug to securing its final approval by the Food and Drug Administration. In this thoroughly updated and expanded second edition of the Handbook of Anticancer Pharmacokinetics and Pharmacodynamics, leading investigators synthesize an invaluable overview of the experimental and clinical processes of anticancer drug development, creating a single indispensable reference that covers all the steps from the identification of cancer-specific molecular targets to screening techniques and the development and validation of bioanalytical methods to clinical trial design and all phases of clinical trials. The authors have included new material on phase 0 trials in oncology, organ dysfunction trials, drug formulations and their impact on anticancer drug PK/PD including strategies to improve drug delivery, pharmacogenomics and cancer therapy, high throughput platforms in drug metabolism and transport pharmacogenetics, imaging in drug development and nanotechnology in cancer. Authoritative and up-to-date, Handbook of Anticancer Pharmacokinetics and Pharmacodynamics, 2nd Edition provides in one comprehensive and highly practical volume a detailed step-by-step guide to the successful design and approval of anticancer drugs. Road map to anticancer drug development from discovery to NDA submission Discussion of molecular targets and preclinical screening Development and validation of bioanalytical methods Chapters on clinical trial design and phase 0, I, II, III clinical trials Pharmacokinetics, pharmacodynamics, pharmacogenomics, and pharmacogenetics of anticancer agents Review of the drug development process from both laboratory and clinical perspectives New technological advances in imaging, high throughput platforms, and nanotechnology in anticancer drug development
Book Synopsis Anticancer Drug Development by : Bruce C. Baguley
Download or read book Anticancer Drug Development written by Bruce C. Baguley and published by Elsevier. This book was released on 2001-11-17 with total page 397 pages. Available in PDF, EPUB and Kindle. Book excerpt: Here in a single source is a complete spectrum of ideas on the development of new anticancer drugs. Containing concise reviews of multidisciplinary fields of research, this book offers a wealth of ideas on current and future molecular targets for drug design, including signal transduction, the cell division cycle, and programmed cell death. Detailed descriptions of sources for new drugs and methods for testing and clinical trial design are also provided. One work that can be consulted for all aspects of anticancer drug development Concise reviews of research fields, combined with practical scientific detail, written by internationally respected experts A wealth of ideas on current and future molecular targets for drug design, including signal transduction, the cell division cycle, and programmed cell death Detailed descriptions of the sources of new anticancer drugs, including combinatorial chemistry, phage display, and natural products Discussion of how new drugs can be tested in preclinical systems, including the latest technology of robotic assay systems, cell culture, and experimental animal techniques Hundreds of references that allow the reader to access relevant scientific and medical literature Clear illustrations, some in color, that provide both understanding of the field and material for teaching
Book Synopsis Cancer Pharmacology by : Ashkan Emadi, MD, PhD
Download or read book Cancer Pharmacology written by Ashkan Emadi, MD, PhD and published by Springer Publishing Company. This book was released on 2023-10-06 with total page 471 pages. Available in PDF, EPUB and Kindle. Book excerpt: Cancer Pharmacology: An Illustrated Manual of Anticancer Drugs, Second Edition is a visually engaging reference detailing the essential basic and clinical science of all approved, effective, and life-prolonging drug therapies in oncology. Now with a greater emphasis on clinical context, application, and management in each chapter, this significantly revised edition provides both early-career and seasoned clinicians with a practical, bench-to-bedside approach and patient-oriented guide. The book provides detailed coverage of the major advances in cancer pharmacology at the forefront of our standards of care for solid tumors and hematologic malignancies, in addition to the basic science that is directly necessary and applicable when at the patient’s bedside. Everything from traditional cytotoxic agents to targeted genomic, epigenomic, hormonal, and immunotherapeutic agents is explored, in addition to a new chapter covering pharmacogenomics. Accompanied by elegant illustrations, each chapter details the tumor microenvironment, chemical structures of agents, pharmacodynamics, pharmacokinetics, pharmacogenomic and molecular properties of the various agents, and their mechanisms of action. The book covers alkylating agents, antimetabolites, antimitotics, epigenetic modulators, hormonal agents, targeted therapies, monoclonal antibodies, immunotherapeutic agents, and much more. Thoroughly updated to include new FDA-approved treatments and applications, and written by leading experts in cancer pharmacology, this second edition continues to be a “must have” for anyone involved in the basic, translational, or clinical aspects of oncology and hematology, including clinicians, pharmacists, nurses, and trainees. Key Features: Over 150 beautiful illustrations depict structures, pharmacokinetics, pharmacodynamics, and pharmacogenomics associated with each class of agents Contains more than 160 high-yield hematology and oncology board-style chapter review questions (more than double the previous edition) with descriptive rationales Describes how chemotherapy, targeted therapy, immunotherapy, and hormonal therapy work, and why they are expected to work adjuvantly, neoadjuvantly, and in combination with other treatment modalities Thoroughly updated and revised chapters cover new FDA drug approvals, disease-site indications, clinical applications and management of drug-to-drug interactions, and toxicities Discusses challenges related to drug development, drug approval, and regulatory issues in relation to anticancer treatments Provides important pharmacotherapy context with clinical pearls in each chapter that help support a patient-oriented, bedside approach
Book Synopsis Handbook of Anticancer Pharmacokinetics and Pharmacodynamics by : William Figg
Download or read book Handbook of Anticancer Pharmacokinetics and Pharmacodynamics written by William Figg and published by Humana Press. This book was released on 2004-03-26 with total page 623 pages. Available in PDF, EPUB and Kindle. Book excerpt: Leading investigators synthesize the entire laboratory and clinical process of developing anticancer drugs to create a single indispensable reference that covers all the steps from the identification of cancer-specific targets to phase III clinical trials. These expert authors provide their best guidance on a wide variety of issues, including clinical trial design, preclinical screening, and the development and validation of bioanalytic methods. The chapters on identifying agents to test in phase III trials and on trial design for the approval of new anticancer agents offer a unique roadmap for moving an agent to NDA submission.
Book Synopsis Antibody-Drug Conjugates by : Kenneth J. Olivier, Jr.
Download or read book Antibody-Drug Conjugates written by Kenneth J. Olivier, Jr. and published by John Wiley & Sons. This book was released on 2016-11-14 with total page 560 pages. Available in PDF, EPUB and Kindle. Book excerpt: Providing practical and proven solutions for antibody-drug conjugate (ADC) drug discovery success in oncology, this book helps readers improve the drug safety and therapeutic efficacy of ADCs to kill targeted tumor cells. • Discusses the basics, drug delivery strategies, pharmacology and toxicology, and regulatory approval strategies • Covers the conduct and design of oncology clinical trials and the use of ADCs for tumor imaging • Includes case studies of ADCs in oncology drug development • Features contributions from highly-regarded experts on the frontlines of ADC research and development
Author :National Academies of Sciences, Engineering, and Medicine Publisher :National Academies Press ISBN 13 :0309457971 Total Pages :145 pages Book Rating :4.3/5 (94 download)
Book Synopsis The Drug Development Paradigm in Oncology by : National Academies of Sciences, Engineering, and Medicine
Download or read book The Drug Development Paradigm in Oncology written by National Academies of Sciences, Engineering, and Medicine and published by National Academies Press. This book was released on 2018-02-12 with total page 145 pages. Available in PDF, EPUB and Kindle. Book excerpt: Advances in cancer research have led to an improved understanding of the molecular mechanisms underpinning the development of cancer and how the immune system responds to cancer. This influx of research has led to an increasing number and variety of therapies in the drug development pipeline, including targeted therapies and associated biomarker tests that can select which patients are most likely to respond, and immunotherapies that harness the body's immune system to destroy cancer cells. Compared with standard chemotherapies, these new cancer therapies may demonstrate evidence of benefit and clearer distinctions between efficacy and toxicity at an earlier stage of development. However, there is a concern that the traditional processes for cancer drug development, evaluation, and regulatory approval could impede or delay the use of these promising cancer treatments in clinical practice. This has led to a number of effortsâ€"by patient advocates, the pharmaceutical industry, and the Food and Drug Administration (FDA)â€"to accelerate the review of promising new cancer therapies, especially for cancers that currently lack effective treatments. However, generating the necessary data to confirm safety and efficacy during expedited drug development programs can present a unique set of challenges and opportunities. To explore this new landscape in cancer drug development, the National Academies of Sciences, Engineering, and Medicine developed a workshop held in December 2016. This workshop convened cancer researchers, patient advocates, and representatives from industry, academia, and government to discuss challenges with traditional approaches to drug development, opportunities to improve the efficiency of drug development, and strategies to enhance the information available about a cancer therapy throughout its life cycle in order to improve its use in clinical practice. This publication summarizes the presentations and discussions from the workshop.
Book Synopsis A Comprehensive Guide to Toxicology in Preclinical Drug Development by : Ali S. Faqi
Download or read book A Comprehensive Guide to Toxicology in Preclinical Drug Development written by Ali S. Faqi and published by Academic Press. This book was released on 2012-11-02 with total page 904 pages. Available in PDF, EPUB and Kindle. Book excerpt: A Comprehensive Guide to Toxicology in Preclinical Drug Development is designed for toxicologists who need a thorough understanding of the drug development process. This multi-contributed reference will provide a detailed picture of the complex and highly interrelated activities of preclinical toxicology in both small molecules and biologics --
Book Synopsis Animal Models in Cancer Drug Discovery by : Asfar Azmi
Download or read book Animal Models in Cancer Drug Discovery written by Asfar Azmi and published by Academic Press. This book was released on 2019-04-16 with total page 470 pages. Available in PDF, EPUB and Kindle. Book excerpt: Animal Models in Cancer Drug Discovery brings forward the most cutting-edge developments in tumor model systems for translational cancer research. The reader can find under this one volume virtually all types of existing and emerging tumor models in use by the research community. This book provides a deeper insight on how these newer models could de-risk modern drug discovery. Areas covered include up to date information on latest organoid derived models and newer genetic models. Additionally, the book discusses humanized animal tumor models for cancer immunotherapy and how they leverage personalized therapies. The chapter on larger animal, canine models and their use in and their use in pre-investigational new drug (pre-IND) development makes the volume unique. Unlike before, the incorporation of several simplified protocols, breeding methodologies, handling and assessment procedures to study drug intervention makes this book a must read. Animal Models in Cancer Drug Discovery is a valuable resource for basic and translational cancer researchers, drug discovery researchers, contract research organizations, and knowledge seekers at all levels in the biomedical field. Encompasses discussions on innovative animal models, xenograft, genetic models, primary models, organoid systems, humanized and other models in modern biology paradigms that are enhancing research in the field of drug discover Covers the use of these models in personalized medicine, immunotherapy, toxicology, pre-IND assessments and related drug development arenas Presents protocols, procedures, and a comprehensive glossary to help new readers understand technical terms and specialized nomenclature
Book Synopsis Cancer Therapeutics by : Beverly A. Teicher
Download or read book Cancer Therapeutics written by Beverly A. Teicher and published by Springer Science & Business Media. This book was released on 1996-12-03 with total page 458 pages. Available in PDF, EPUB and Kindle. Book excerpt: Cancer drug discovery has been and continues to be a process of ingenuity, serendip ity, and dogged determination. In an effort to develop and discover better therapies against cancer, investigators all over the world have increased our knowledge of cell biology, biochemistry, and molecular biology. The goal has been to define therapeuti cally exploitable differences between normal and malignant cells. The result has been an increased understanding of cellular and whole-organism biology and an increased respect for the flexibility and resiliency ofbiologically systems. Thus, as some new therapeutic targets have been defined and new therapeutic strategies have been attempted, so have some new biological hurdles resulting from tumor evasion of the intended therapeutic attack been discovered. Historically, anticancer drugs have originated from all available chemical sources. Synthetic molecules from the chemical industry, especially dyestuffs and warfare agents, and natural products from plants, microbes, and fungi have all been potential sources of pharmaceuticals, including anticancer agents. There is no shortage of molecules; the challenge has been and continues to be methods of identifying molecules that have the potential to be therapeutically important in human malignant disease. "Screening" remains the most important and most controversial method in cancer drug discovery. In vitro screens have generally focused on cytotoxicity and have identified several highly cytotoxic molecules. Other endpoints available in vitro are inhibition of proliferation, 3 inhibition of [ H]thymidine incorporation into DNA and various viability assays, based most frequently on dye exclusion or metabolism.
Author :Siamak Cyrus Khojasteh Publisher :Springer Science & Business Media ISBN 13 :1441956298 Total Pages :214 pages Book Rating :4.4/5 (419 download)
Book Synopsis Drug Metabolism and Pharmacokinetics Quick Guide by : Siamak Cyrus Khojasteh
Download or read book Drug Metabolism and Pharmacokinetics Quick Guide written by Siamak Cyrus Khojasteh and published by Springer Science & Business Media. This book was released on 2011-04-07 with total page 214 pages. Available in PDF, EPUB and Kindle. Book excerpt: Drug Metabolism and Pharmacokinetics Quick Guide covers a number of aspects of drug assessment at drug discovery and development stages, topics such as pharmacokinetics, absorption, metabolism, enzyme kinetics, drug transporters, drug interactions, drug-like properties, assays and in silico calculations. It covers key concepts, with useful tables on physiological parameters (eg. blood flow to organs in x-species, expression and localization of enzymes and transporters), chemical structure, nomenclature, and moieties leading to bioactivation (with examples). Overall it includes a number of key topics useful at the drug discovery stage, which would serve as a quick reference with several examples from the literature to illustrate the concept.
Book Synopsis Phase I Oncology Drug Development by : Timothy A. Yap
Download or read book Phase I Oncology Drug Development written by Timothy A. Yap and published by Springer Nature. This book was released on 2020-09-16 with total page 352 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book provides a detailed review of how oncology drug development has changed over the past decade, and serves as a comprehensive guide for the practicalities in setting up phase I trials. The book covers strategies to accelerate the development of novel antitumor compounds from the laboratory to clinical trials and beyond through the use of innovative mechanism-of-action pharmacodynamic biomarkers and pharmacokinetic studies. The reader will learn about all aspects of modern phase I trial designs, including the incorporation of precision medicine strategies, and approaches for rational patient allocation to novel anticancer therapies. Circulating biomarkers to assess mechanisms of response and resistance are changing the way we are assessing patient selection and are also covered in this book. The development of the different classes of antitumor agents are discussed, including chemotherapy, molecularly targeted agents, immunotherapies and also radiotherapy. The authors also discuss the lessons that the oncology field has learnt from the development of hematology-oncology drugs and how such strategies can be carried over into therapies for solid tumors. There is a dedicated chapter that covers the specialized statistical approaches necessary for phase I trial designs, including novel Bayesian strategies for dose escalation. This volume is designed to help clinicians better understand phase I clinical trials, but would also be of use to translational researchers (MDs and PhDs), and drug developers from academia and industry interested in cancer drug development. It could also be of use to phase I trial study coordinators, oncology nurses and advanced practice providers. Other health professionals interested in the treatment of cancer will also find this book of great value.
